Coherus押注“癌症联合治疗”：能真正延长患者生命吗？

Minhua笔记02-22

过去十年，PD‑1 免疫检查点抑制剂的出现改变了肿瘤治疗格局，默沙东的 Keytruda（帕博利珠单抗）更是成长为数百亿美元级的重磅产品。但 Keytruda 单药仅对 20%–30% 的患者有效，仍有大量患者需要更好的方案。Coherus Oncology CEO Denny Lanfear 指出，这正推动行业从单一药物转向多靶点、多机制的联合治疗，能同时攻击肿瘤的多个方面，或增强 PD‑1 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2613427508?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-22 23:38","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2613427508","market":"hk","top_or_hot":-1,"title":"Coherus押注“癌症联合治疗”：能真正延长患者生命吗？","media":"Minhua笔记","content":"<div>\n<p>过去十年，PD‑1 免疫检查点抑制剂的出现改变了肿瘤治疗格局，默沙东的 Keytruda（帕博利珠单抗）更是成长为数百亿美元级的重磅产品。但 Keytruda 单药仅对 20%–30% 的患者有效，仍有大量患者需要更好的方案。Coherus Oncology CEO Denny Lanfear 指出，这正推动行业从单一药物转向多靶点、多机制的联合治疗，能同时攻击肿瘤的多个方面，或增强 PD‑1 ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260222234123a4bc7d66&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus押注“癌症联合治疗”：能真正延长患者生命吗？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus押注“癌症联合治疗”：能真正延长患者生命吗？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-22 23:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260222234123a4bc7d66&s=b><strong>Minhua笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>过去十年，PD‑1 免疫检查点抑制剂的出现改变了肿瘤治疗格局，默沙东的 Keytruda（帕博利珠单抗）更是成长为数百亿美元级的重磅产品。但 Keytruda 单药仅对 20%–30% 的患者有效，仍有大量患者需要更好的方案。Coherus Oncology CEO Denny Lanfear 指出，这正推动行业从单一药物转向多靶点、多机制的联合治疗，能同时攻击肿瘤的多个方面，或增强 PD‑1 ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260222234123a4bc7d66&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260222234123a4bc7d66&s=b","article_id":"2613427508","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260222234123a4bc7d66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613427508","pubTimestamp":1771774702,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"过去十年，PD1 免疫检查点抑制剂的出现改变了肿瘤治疗格局，默沙东的 Keytruda更是成长为数百亿美元级的重磅产品。但 Keytruda 单药仅对 20%–30% 的患者有效，仍有大量患者需要更好的方案。Coherus Oncology CEO Denny Lanfear 指出，这正推动行业从单一药物转向多靶点、多机制的联合治疗，能同时攻击肿瘤的多个方面，或增强 PD1 药物的免疫效应。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","01877":"君实生物","BK1583":"高瓴概念","BK1515":"抗疫概念"},"translate_title":"Coherus Bets on \"Combined Cancer Therapy\": Can It Really Prolong Patient Life?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":0.9},"content_text":"过去十年，PD‑1 免疫检查点抑制剂的出现改变了肿瘤治疗格局，默沙东的 Keytruda（帕博利珠单抗）更是成长为数百亿美元级的重磅产品。但 Keytruda 单药仅对 20%–30% 的患者有效，仍有大量患者需要更好的方案。Coherus Oncology CEO Denny Lanfear 指出，这正推动行业从单一药物转向多靶点、多机制的联合治疗，能同时攻击肿瘤的多个方面，或增强 PD‑1 药物的免疫效应。单药试验正在减少，联合治疗成为主流趋势2007 年：约 70% 的肿瘤临床试验是单药2021 年：这一比例已降至 30% 以下Moderna、默沙东、艾伯维等巨头都在布局“两药甚至更多的药物组合”。一些组合已展现出积极信号：Trodelvy（戈沙妥珠单抗）+ Keytruda：在三阴乳腺癌中显著延缓疾病进展Moderna 个体化新抗原 mRNA 疫苗 + Keytruda：在高风险黑色素瘤中将复发或死亡风险降低近 50%Coherus 首席研发官 Theresa LaVallee 表示：““PD‑1 单药有效，但它们最大的成功来自能增强免疫系统的联合方案。”风险与收益：更强疗效 vs. 更高毒性Coherus 正围绕联合策略构建管线。与强生合作，将其早期药物 tagmokitug（抗 CCR8 细胞毒抗体）与强生的 pasritamig 联合用于前列腺癌tagmokitug 也正在与 Coherus 从君实生物获得授权的 PD‑1 抗体 Loqtorzi（特瑞普利单抗）联合，用于结直肠、头颈、胃和食管癌联合策略的逻辑是：PD‑1 激活免疫，但许多肿瘤内部缺乏 T 细胞；tagmokitug 可帮助外周 T 细胞更有效进入肿瘤。一些早期数据也显示联合治疗确实在改善结局：一项综述显示，在晚期肺癌中，联合治疗相比单药可提升 3.8 个月总体生存期（OS）、1.9 个月无进展生存期（PFS）但代价是：严重不良事件增加。如何在疗效与毒性之间取得平衡，是联合治疗的核心挑战。不过，也有组合没有显著增加毒性。例如：Coherus 的抗 IL‑27 抗体 casdozokitug 联合标准化疗用于肝癌未显著增加严重不良反应肿瘤清除率从 8% → 17%多靶点策略或为难治肿瘤带来新希望LaVallee 总结道：““免疫治疗真正的机会在于长期生存甚至缓解，而联合治疗正在提升这种可能性。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613427508","isCrawlerRequest":true}